Disclosed are pharmaceutical composition comprising a) a therapeutically effective amount of a sodium salt of the compound of formula (I) (4-{ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl} -cyclohexyl)-acetic acid (Pradigastat), b) one or more surfactants selected from sodium lauryl sulfate, stearic acid, palmitic acid, myristic acid, poloxamers and polyethylene glycols or a combination thereof, and wherein the surfactant is present in an amount which is 0.1 to 5% by weight of the tablet c) one or more dry binders selected from hydroxypropylmethyl cellulose or hydroxypropyl cellulose, both of medium to high viscosity and wherein the dry binder is present in an amount which is 2 to 20% by weight of the tablet d) one or more fillers selected from microcrystalline cellulose, Anhydrous Dicalcium Phosphate, Anhydrous Lactose, and combinations thereof, and wherein the filler is present in an amount which is 4% to 85%, by weight of the tablet, and e) one or more disintegrants, wherein the disintegrant is selected from crosscarmellose sodium, cross-linked polyvinyl pyrrolidone, and Sodium Starch Glycollate, and wherein the disintegrant is present in an amount which is 1-10% by weight of the tablet. Also disclosed is the use of the compositions in the manufacture of a medicament for the treatment of a condition or disorder associated with DGAT1 activity including obesity, diabetes, cardiovascular diseases, neoplastic diseases and dermatological disorders.
